WSJ's blog on health and the business of health.

Visit WSJ.com: Health Blog

Pfizer to Cut R&D Jobs, Retreat from Heart-Drug Research

Posted on September 30, 2008

In its ongoing struggle to re-invent itself, Pfizer s going to announce today that it s cutting R&D staff and largely getting out of the business of making new medicines for heart disease, the WSJ reports.It s also largely bailing on research in anemia, osteoporosis, liver disease, muscle disease, obesity, and peripheral artery disease, Forbes reports, citing a memo from Pfizer R&D chief Martin Mackay. To read the memo, click on the PDF icon at the right.Instead, Forbes says, the company will focus on five therapeutic areas: Alzheimers; diabetes; immune disorders and inflammation; cancer...

Original article link


alzheimers , arthritis , cancer , cholesterol , diabetes , heart disease , liver , mental illness , obesity , osteoporosis , rheumatoid arthritis , schizophrenia